GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
K

Kyorin Pharmaceutical Co 4569.T · JPY

Health Care · Tokyo Stock Exchange · 🇯🇵 Japan

Compare

1,098

+1.29%

Close of 9 Nov 2026, in JPY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in JPY, from our data supplier.

FY2026

Revenue

¥126.26bn

FY2017FY2026

Net income

¥3.45bn

FY2017FY2026

Free cash flow

¥2.52bn

FY2017FY2026

Shareholders' equity

¥142.43bn

FY2017FY2026

Income statement

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue¥126.26bn¥130.09bn¥119.53bn¥113.27bn¥105.53bn¥102.90bn¥109.98bn¥113.62bn¥110.64bn¥115.37bn
Gross profit¥51.61bn¥59.51bn¥51.62bn¥50.16bn¥49.44bn¥51.62bn¥57.02bn¥57.40bn¥61.56bn¥64.53bn
Research and development¥12.06bn¥10.51bn¥8.02bn¥10.90bn¥8.90bn¥9.70bn¥10.99bn¥10.79bn¥14.24bn¥13.57bn
Operating income¥3.57bn¥12.55bn¥6.23bn¥5.12bn¥5.00bn¥5.78bn¥7.49bn¥8.96bn¥8.81bn¥10.41bn
Net income¥3.45bn¥9.09bn¥5.47bn¥4.72bn¥3.93bn¥6.13bn¥6.15bn¥6.87bn¥6.57bn¥7.30bn
Diluted earnings per share60.02158.1695.3082.2168.62106.98107.31119.91101.6499.16

Balance sheet

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assets¥195.46bn¥193.62bn¥177.63bn¥176.04bn¥171.92bn¥167.13bn¥171.16bn¥173.03bn¥196.74bn¥192.67bn
Cash and short-term investments¥15.08bn¥16.51bn¥13.98bn¥19.39bn¥27.49bn¥30.84bn¥32.92bn¥32.51bn¥44.72bn¥48.63bn
Total liabilities¥53.02bn¥57.33bn¥46.89bn¥50.58bn¥47.41bn¥42.46bn¥48.45bn¥49.64bn¥33.43bn¥34.81bn
Debt¥23.79bn¥28.44bn¥20.95bn¥21.28bn¥21.62bn¥21.88bn¥23.59bn¥24.02bn¥5.34bn¥5.68bn
Shareholders' equity¥142.43bn¥136.28bn¥130.74bn¥125.46bn¥124.51bn¥124.66bn¥122.71bn¥123.39bn¥163.30bn¥157.84bn
Shares outstanding57m57m57m57m57m57m57m57m65m74m

Cash flow

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations¥6.38bn¥3.51bn¥1.55bn¥2.01bn¥6.35bn¥5.19bn¥7.74bn¥340.0m¥10.46bn¥16.39bn
Capital spending−¥3.86bn−¥5.70bn−¥5.78bn−¥9.40bn−¥2.69bn−¥5.12bn−¥3.22bn−¥2.17bn−¥3.39bn−¥2.21bn
Free cash flow¥2.52bn−¥2.19bn−¥4.23bn−¥7.40bn¥3.66bn¥65.0m¥4.52bn−¥1.83bn¥7.07bn¥14.18bn
Dividends paid−¥3.30bn−¥3.02bn−¥3.01bn−¥3.02bn−¥3.77bn−¥4.35bn−¥4.35bn−¥5.07bn−¥4.33bn−¥4.32bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue¥29.65bn¥33.80bn¥33.73bn¥28.50bn¥30.23bn¥40.80bn¥34.15bn¥26.72bn
Gross profit¥12.18bn¥12.09bn¥14.63bn¥11.63bn¥13.26bn¥20.86bn¥15.10bn¥11.21bn
Operating income¥966.0m−¥1.03bn¥3.24bn−¥1.01bn¥2.37bn¥9.45bn¥1.56bn¥398.0m
Net income¥824.0m−¥671.0m¥2.63bn−¥606.0m¥2.10bn¥6.65bn¥1.18bn¥370.0m
Diluted earnings per share14.34-11.6845.69-10.5536.55115.7020.616.44
Total assets¥188.61bn¥195.46bn¥194.27bn¥186.01bn¥190.57bn¥193.62bn¥190.49bn¥178.87bn
Cash and short-term investments¥16.95bn¥15.08bn¥17.81bn¥15.13bn¥16.62bn¥16.51bn¥15.51bn¥14.52bn
Debt¥2.85bn¥23.45bn¥9.29bn¥22.43bn¥6.30bn¥27.97bn¥18.30bn¥24.64bn
Shareholders' equity¥140.30bn¥142.43bn¥138.87bn¥136.45bn¥136.15bn¥136.28bn¥130.07bn¥130.03bn

Growth per year

Compound annual rate

3 years5 years10 years
Revenue3.7%4.2%0.6%
Operating income-11.4%-9.2%-15.7%
Net income-10.0%-10.9%-12.8%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin43.4%43.5%45.0%49.5%
Operating margin6.3%5.6%5.5%7.4%
Net margin4.9%4.6%4.7%5.8%

Valuation history

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Price to earnings19.19.715.821.625.117.318.115.923.621.3
Price to sales0.50.70.70.90.91.01.01.01.41.4

Dividends and splits

Per share, in the currency the company pays

Paid for 20 years. Last went ex-dividend on 29 Sept 2026.

FY2027FY2026FY2025FY2024FY2023FY2022FY2021FY2020
Paid in the year10.0089.0052.0052.0052.0065.0075.0075.00
  • 1-to-1 reverse split · 20 Dec 2006
  • 1-to-1 reverse split · 10 Mar 2006

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.